TABLE 1.

Sources, antimicrobial susceptibilities, IEF profiles, and PFGE profiles of the nine epidemiologically unrelated PER-1-producing P. aeruginosa clinical isolates investigated in this study

HospitalIsolateDateWardaSpecimenb typeMIC of antibiotic (μg/ml)cpIS by IEFdPFGE pattern
CZFPATPIPTIPMECPGMTONEAK
San Matteo, PaviaPa34SMNovember 1997HAEMCutaneous swab>32>32>323232>16>16>4>16>16>32>645.3, 8.0A
Pa50SMMarch 1998PAED-SUUrine>32>32>32>128>128>16>16>4>16>16>32325.3, 8.3C
Pa66SMApril 1998ICUCutaneous swab>32>32>32>128>128<4>16>4>16>16>32>645.3, 8.0D
TreviglioPa105TRSeptember 1995ICUBAW>32>32>326416≤4>16>4>16>16>32325.3, 8.0F0
Pa144TRSeptember 1998ICUBAW>32>32>32>12816>16>16>4>16>16>32>645.3, 8.0F1
Pio Albergo Trivulzio, MilanPs101PATAugust 1999LCTFUrine>32>32>32>128>128>16>16>4>16>16>32>645.3, 6.9, 8.2E
Niguarda, MilanPa6NIFebruary 1999BMTPharyngeal swab>32>32>323216>16>16>4>16>16>32>645.3, 8.0A
Pa40NI00February 2000HAEMPharyngeal swab>32>32>3216≤8≤4>16≤1>16>16>32>645.3, 8.4B
SondaloPa1309SODecember 1999NSUSputum>32>32>323216>16>16>4>16>16>32>645.3, 8.0G
  • a HAEM, hematology; PAED-SU, pediatric surgery; LCTF, long-term care facility; BMT, bone marrow transplantation unit; NSU, neurosurgery.

  • b BAW, bronchoalveolar washing.

  • c CZ, ceftazidime; FP, cefepime; AT, aztreonam; PI, piperacillin; PT, piperacillin-tazobactam (tazobactam at a fixed concentration of 4 μg/ml); IP, imipenem; ME, meropenem; CP, ciprofloxacin; GM, gentamicin; TO, tobramycin; NE, netilmicin; AK, amikacin.

  • d pls of β-lactamase activities in crude cell extracts, as detected by analytical IEF. In the bioassay, the pI 5.3 enzyme always exhibited activity against cefotaxime, ceftazidime, cefepime, and aztreonam; the pI 6.9 enzyme of isolate Ps101PAT exhibited activity against ceftazidime, cefepime, and aztreonam; and the pI 8.0 to 8.4 enzymes did not exhibit ESBL activity.